Related Experiment Video
Updated: May 23, 2026
06:38
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Sorafenib in liver cancer
1Pusan National University School of Medicine and Medical Research Institute, Pusan National University Hospital, Department of Internal Medicine, 1-10 Ami-dong, Seo-Gu, Busan 602-739, Korea.
Expert Opinion on Pharmacotherapy
|April 24, 2012
Summary
Sorafenib, a multikinase inhibitor, is an approved standard therapy for advanced hepatocellular carcinoma (HCC). Further research into sorafenib
Area of Science:
- Oncology
- Molecular targeted therapy
Background:
- Targeted therapies represent a significant advancement in cancer treatment, driven by increased understanding of carcinogenesis.
- Sorafenib, an oral multikinase inhibitor, targets key signaling pathways including Raf/mitogen-activated protein (MAP) kinase/extracellular signal-regulated kinase (ERK) and vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR).
- Sorafenib has demonstrated efficacy in treating hepatocellular carcinoma (HCC).
Purpose of the Study:
- To provide an updated summary of preclinical and clinical experience with sorafenib in HCC.
- To review existing data to inform future therapeutic strategies.
Main Methods:
- Literature review of preclinical and clinical studies on sorafenib in HCC.
- Data compilation from international conference abstracts and peer-reviewed journal articles.
- Literature search conducted up to December 2011.
Main Results:
- Sorafenib has shown favorable outcomes in preclinical and clinical trials for HCC.
- The drug has been approved as a standard treatment for advanced HCC based on available data.
Conclusions:
- Sorafenib is established as a standard therapy for advanced HCC.
- Continued investigation is needed to fully elucidate the multifaceted roles of sorafenib in HCC treatment.
- Data generated from sorafenib studies will be instrumental in the development of novel therapeutic agents for HCC.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...